SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $33
SVB Leerink analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $32 to $33.
Analyst Expectations for Ionis Pharmaceuticals’s Future
Over the past 3 months, 5 analysts have published their opinion on Ionis Pharmaceuticals (NASDAQ:IONS) stock. These analysts…
The Latest Analyst Ratings for Ionis Pharmaceuticals
Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Benzinga’s Top Ratings Upgrades, Downgrades For December 21, 2022
Upgrades For PagSeguro Digital Ltd (NYSE:PAGS), New Street Research upgraded the previous rating of Neutral to Buy. In…
SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $26
SVB Leerink analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $30 to $26.
Ionis Pharmaceuticals Q3 Sales $160.00M Beat $143.84M Estimate
Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly sales of $160.00 million which beat the analyst consensus estimate of $143.84 million by 11.23 percent. This is a 20.30 percent increase over sales of $133.00
Ionis Highlights Data From GSK’s Phase 2b Clinical Study Of Bepirovirsen
onis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced topline data from the Phase 2b SOLANO study of ION449 (AZD8233) for hypercholesterolemia (high cholesterol levels).…
There’s ‘Outsized’ Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
Morgan Stanley has assumed coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with an Overweight (previously Underweight) rating and a price target of $57 from…